Latest news for Minco Cap (OTC:MGHCF) Stock

Minco Capital Corp is focused on utilizing its working capital position, industry contacts and internal expertise to identify, evaluate and invest in assets that have the capacity to generate returns and growth. The company invests in publicly traded and privately held corporations as well as taking indirect and direct ownership stakes in resource projects. Its types of investments may include common shares, preferred shares, warrants, royalties, convertible debentures, bridge loans, and other investment vehicles. It has one segment which is the acquisition and sale of investments in other companies.

Minco Capital Corp

Goldman Sachs analyst Richard Ramsden maintains Lazard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAZ#NYSE">LAZ</a>) with a Sell and raises the price target from $38 to $42.

News

Price Target

Analyst Ratings

Goldman Sachs Maintains Sell on Lazard, Raises Price Target to $42

Eni S.p.A.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/E#NYSE">E</a>) shares are trading higher after the company reported Q2 FY24 pro forma adjusted EBIT of €4.1 billion, down 8% Y/Y, in the <a target="_blank" href="https://www.eni.com/content/dam/enicom/documents/press-release/migrated/2024-en/07/PR-2024-second-quarter-results.pdf" rel="noreferrer noopener">quarter</a>.
Hydrocarbon production rose 6% Y/Y to €1,712 kboe/d, with installed capacity from renewables of 3.1 GW at the end of the period.
Production benefitted from a continued ramp-up of the company&#8217;s flagship projects in Côte d&#8217;Ivoire and Congo Floating LNG, a higher contribution from Libya, and the full integration of Neptune.
In Q2 2024, E&amp;P proforma adjusted EBIT was €3.5 billion, up 26% Y/Y, fueled by higher production and efficiency gains.
GGP proforma adjusted EBIT stood at €0.33 billion, reflecting ongoing optimization of the gas and LNG portfolio.
Adjusted net profit stood at €1.5 billion, down 21% Y/Y, in the quarter but above an analyst consensus of €1.42 billion (as per Reuters).
Cash flow from operations before changes in working capital at replacement cost fell 8% Y/Y to €3.91 billion.
CEO Claudio Descalzi stated, "We are upgrading our Upstream portfolio, having recently announced the divestment of our non-core assets in Alaska, the ongoing completion of the sale of onshore Nigeria, and agreed a combination with Ithaca Energy for our UK assets.&#8221;
Apart from this, PETRONAS, Eni&#8217;s Enilive S.p.A, and Euglena Co. finalized the investment decision to build a biorefinery at PETRONAS&#8217; Pengerang Integrated Complex (PIC) in Johor, <a target="_blank" href="https://www.eni.com/en-IT/media/press-release/2024/07/petronas-enilive-and-euglena-reach-final-investment-decision-to-construct-a-biorefinery-in-malaysia.html" rel="noreferrer noopener">Malaysia</a>.
The biorefinery, slated for completion in late 2028, will produce Sustainable Aviation Fuel (SAF) and other biofuels.
Construction starts in Q4 2024, and the facility will process 650,000 tonnes of raw materials per year to produce SAF, HVO, and bio-naphtha.
Outlook: The company projects hydrocarbon production to reach the upper end of the 1.69 &#8211; 1.71 million boe/d range, <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">given a forecast Brent price of $86/bbl</a>.
The company now expects proforma adjusted EBIT of around €15 billion, with adjusted CFFO before working capital expected to exceed €14 billion for the year.
Eni anticipates the next quarterly dividend, following shareholder approval of a €1 per share dividend for FY 2024 (a 6% increase from 2023), will be €0.25 per share, payable on Sept. 25, 2024.
After shareholder approval of a new €3.5 billion buyback plan, management confirms a 2024 buyback of €1.6 billion, with a faster pace of repurchases than previously planned.
The company&#8217;s disposal plan is advancing ahead of schedule, with nearly all of the €8 billion net proceeds over the four-year period now clearly visible.
This week, Eni secures an exclusivity agreement with KKR to sell a 20%-25% <a target="_blank" href="https://www.benzinga.com/markets/equities/24/07/39914011/italys-eni-nears-deal-to-sell-enilive-stake-to-kkr-details" rel="noreferrer noopener">stake in Enilive, valuing it at €11.5 billion-€12.5 billion</a>.
Investors can gain exposure to Eni via&nbsp;The Advisors? Inner Circle Fund Cambiar Aggressive Value ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAMX#NYSE">CAMX</a>).
Price Action: E shares are up 4.23% at $31.57 at last check Friday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo: Shutterstock

Earnings

Equities

Large Cap

Guidance

Dividends

Commodities

Buybacks

Movers

CAMX

Eni's Q2 Profit Declines But Beats Expectations: Shares Rise On Strong Production

Deep-pocketed investors have adopted a bearish approach towards Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AMGN usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Amgen. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 37% leaning bullish and 62% bearish. Among these notable options, 6 are puts, totaling $287,160, and 2 are calls, amounting to $67,000.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $315.0 and $355.0 for Amgen, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Amgen's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Amgen's whale activity within a strike price range from $315.0 to $355.0 in the last 30 days. 
<h3>Amgen Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722004272_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$12.5</td>
<td>$12.4</td>
<td>$12.5</td>
<td>$325.00</td>
<td>$67.4K</td>
<td style="text-align: right;">789</td>
<td style="text-align: right;">98</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$31.75</td>
<td>$30.3</td>
<td>$31.75</td>
<td>$320.00</td>
<td>$63.5K</td>
<td style="text-align: right;">162</td>
<td style="text-align: right;">25</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$30.55</td>
<td>$30.5</td>
<td>$30.55</td>
<td>$340.00</td>
<td>$61.1K</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">20</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$14.45</td>
<td>$14.45</td>
<td>$14.45</td>
<td>$330.00</td>
<td>$36.1K</td>
<td style="text-align: right;">253</td>
<td style="text-align: right;">50</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/09/24</td>
<td>$3.45</td>
<td>$2.57</td>
<td>$3.45</td>
<td>$355.00</td>
<td>$34.5K</td>
<td style="text-align: right;">16</td>
<td style="text-align: right;">100</td>
</tr>
</tbody>
</table>

<h3>About Amgen</h3>
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
<h3>Current Position of Amgen</h3>
<ul>
<li>Currently trading with a volume of 164,369, the AMGN's price is down by -0.04%, now at $334.17. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 11 days.</li>
</ul>
<h3>Expert Opinions on Amgen</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $321.5.
<ul>
<li>An analyst from Argus Research has decided to maintain their Buy rating on Amgen, which currently sits at a price target of $340. </li>
<li>An analyst from Morgan Stanley has decided to maintain their Equal-Weight rating on Amgen, which currently sits at a price target of $303. </li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Amgen, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

AMGN

Unpacking the Latest Options Trading Trends in Amgen

CORRECTION: Colgate Raised FY24 Organic Sales Growth Guidance From 5-7% To 6-8%

High-rolling investors have positioned themselves bullish on JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in JPM often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 8 options trades for JPMorgan Chase. This is not a typical pattern.
The sentiment among these major traders is split, with 50% bullish and 25% bearish. Among all the options we identified, there was one put, amounting to $25,200, and 7 calls, totaling $367,160.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $205.0 to $220.0 for JPMorgan Chase during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in JPMorgan Chase's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to JPMorgan Chase's substantial trades, within a strike price spectrum from $205.0 to $220.0 over the preceding 30 days.
<h3>JPMorgan Chase Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722004266_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JPM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$5.8</td>
<td>$5.75</td>
<td>$5.75</td>
<td>$215.00</td>
<td>$115.8K</td>
<td>9.7K</td>
<td style="text-align: right;">466</td>
</tr>
<tr>
<td>JPM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$7.85</td>
<td>$7.7</td>
<td>$7.85</td>
<td>$215.00</td>
<td>$62.8K</td>
<td>2.2K</td>
<td style="text-align: right;">99</td>
</tr>
<tr>
<td>JPM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$10.65</td>
<td>$10.6</td>
<td>$10.65</td>
<td>$220.00</td>
<td>$53.2K</td>
<td>5.2K</td>
<td style="text-align: right;">50</td>
</tr>
<tr>
<td>JPM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$7.6</td>
<td>$7.45</td>
<td>$7.45</td>
<td>$210.00</td>
<td>$37.2K</td>
<td>7.4K</td>
<td style="text-align: right;">60</td>
</tr>
<tr>
<td>JPM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/02/24</td>
<td>$3.55</td>
<td>$3.5</td>
<td>$3.5</td>
<td>$210.00</td>
<td>$37.1K</td>
<td>2.0K</td>
<td style="text-align: right;">415</td>
</tr>
</tbody>
</table>

<h3>About JPMorgan Chase</h3>
JPMorgan Chase is one of the largest and most complex financial institutions in the United States, with nearly $3.9 trillion in assets. It is organized into four major segments--consumer and community banking, corporate and investment banking, commercial banking, and asset and wealth management. JPMorgan operates, and is subject to regulation, in multiple countries.
Having examined the options trading patterns of JPMorgan Chase, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is JPMorgan Chase Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 1,231,982, the JPM's price is up by 1.27%, now at $211.31. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 77 days.</li>
</ul>
<h3>Expert Opinions on JPMorgan Chase</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $221.6.
<ul>
<li>Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on JPMorgan Chase with a target price of $217. </li>
<li>Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for JPMorgan Chase, targeting a price of $221. </li>
<li>Consistent in their evaluation, an analyst from Jefferies keeps a Buy rating on JPMorgan Chase with a target price of $239. </li>
<li>Consistent in their evaluation, an analyst from Evercore ISI Group keeps a Outperform rating on JPMorgan Chase with a target price of $210. </li>
<li>Maintaining their stance, an analyst from Oppenheimer continues to hold a Outperform rating for JPMorgan Chase, targeting a price of $221. </li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest JPMorgan Chase options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

What the Options Market Tells Us About JPMorgan Chase

Manhattan Associates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>) has outperformed the market over the past 10 years by 13.22% on an annualized basis producing an average annual return of 24.11%. Currently, Manhattan Associates has a market capitalization of $15.12 billion. 
Buying $1000 In MANH: If an investor had bought $1000 of MANH stock 10 years ago, it would be worth $8,234.71 today based on a price of $246.87 for MANH at the time of writing.
<h3>Manhattan Associates's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722004262_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

MANH

If You Invested $1000 In This Stock 10 Years Ago, You Would Have $8,200 Today

Financial giants have made a conspicuous bullish move on Palantir Technologies. Our analysis of options history for Palantir Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) revealed 8 unusual trades.
Delving into the details, we found 62% of traders were bullish, while 37% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $391,161, and 6 were calls, valued at $337,300.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $25.0 to $40.0 for Palantir Technologies during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Palantir Technologies's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Palantir Technologies's significant trades, within a strike price range of $25.0 to $40.0, over the past month.
<h3>Palantir Technologies Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722004261_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PLTR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$9.75</td>
<td>$9.65</td>
<td>$9.75</td>
<td>$36.00</td>
<td>$239.8K</td>
<td>9</td>
<td>156</td>
</tr>
<tr>
<td>PLTR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$9.7</td>
<td>$9.65</td>
<td>$9.7</td>
<td>$36.00</td>
<td>$151.3K</td>
<td>9</td>
<td>156</td>
</tr>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$4.2</td>
<td>$4.15</td>
<td>$4.15</td>
<td>$30.00</td>
<td>$124.5K</td>
<td>5.8K</td>
<td>303</td>
</tr>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/02/24</td>
<td>$0.42</td>
<td>$0.4</td>
<td>$0.42</td>
<td>$28.00</td>
<td>$63.1K</td>
<td>14.9K</td>
<td>2.7K</td>
</tr>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$4.35</td>
<td>$4.25</td>
<td>$4.25</td>
<td>$40.00</td>
<td>$42.5K</td>
<td>23.0K</td>
<td>303</td>
</tr>
</tbody>
</table>

<h3>About Palantir Technologies</h3>
Palantir is an analytical software company that focuses on leveraging data to create efficiencies in its clients' organizations. The firm serves commercial and government clients via its Foundry and Gotham platforms, respectively. The Denver-based company was founded in 2003 and went public in 2020.
After a thorough review of the options trading surrounding Palantir Technologies, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Palantir Technologies Standing Right Now?</h3>
<ul>
<li>With a trading volume of 7,386,589, the price of PLTR is up by 1.78%, reaching $27.11.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 10 days from now.</li>
</ul>
<h3>Expert Opinions on Palantir Technologies</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $22.0.
<ul>
<li>An analyst from Mizuho has revised its rating downward to Underperform, adjusting the price target to $22. </li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Palantir Technologies, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

PLTR

Unpacking the Latest Options Trading Trends in Palantir Technologies

Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) has outperformed the market over the past 5 years by 7.0% on an annualized basis producing an average annual return of 19.54%. Currently, Marvell Tech has a market capitalization of $56.77 billion. 
Buying $1000 In MRVL: If an investor had bought $1000 of MRVL stock 5 years ago, it would be worth $2,403.96 today based on a price of $65.58 for MRVL at the time of writing.
<h3>Marvell Tech's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722004258_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MRVL

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,400 Today

Personal finance guru Dave Ramsey gave tough advice on The Ramsey Show to a woman and her husband living paycheck to paycheck yet making $11,500 a month. Here's what advice Ramsey gave the couple.&nbsp;
Alyssa called in for guidance from the finance expert because she and her husband were worried about finances. Alyssa tells Ramsey that she's remarried, and together as a couple, they bring in $11,500 per month, yet they're unable to <a href="http://www.benzinga.com/money/smartasset">contribute to their retirement</a> and only have around $3,000 in their savings.&nbsp;
Don't Miss:
<ul>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/red-ventures"> The percentage may shock you</a>.</li>
<li>Are you richer than most people you know?<a href="https://www.benzinga.com/money/are-you-richer-than-most-people"> Here&#8217;s the net worth you need at every age to be above average.</a></li>
</ul>
Earning a combined salary puts the couple at an annual salary of $140,000, much higher than the average annual salary in the U.S. For example, USA Today reported that the U.S. Bureau of Labor released findings that the average American earned $59,384. Even with the amount doubled, Alyssa and her husband earn significantly more. So, why are they living paycheck to paycheck? This is what Ramsey wants to find out.&nbsp;
He starts by finding out how much debt the pair have, and Alyssa reveals that combined, they have $138,000 in debt, with $90,000 of it from Alyssa's studies to become a mental health care therapist. Her husband has the remaining $40,000 from his time at college, even though he did not want to attend college. But that wasn't all. They still owed an additional $60,000 on car payments and a mortgage with $240,000 still to go. So, the total debt is more than $130,000.&nbsp;
Ramsey's co-host, George Kamel, an expert on all things money, questions Alyssa about how quickly they can pay this debt off. He asks if they can throw up to $5,000 per month at the smallest debt. Alyssa's sigh of hesitance worries Kamel, and he asks her what is holding her back from zapping her debt away.&nbsp;
See Also: How much money will a $200,000 annuity pay out each month?<a href="https://www.benzinga.com/money/200k-annuities-adv"> The numbers may shock you.</a>
Alyssa&#8217;s fear of taking $5,000 per month to pay off debt is motivated by ensuring her daughter has enough. Because Alyssa is self-employed and her husband works in construction, she reveals that she gets worried about "catastrophic expenses." But that's not what Ramsey was worried about listening to her talk.&nbsp;
He tells her, "You know what I'm worried about?" and dishes out some hard truths, "You make $130,000 a year and you're freaking broke. That's what I'm worried about." Ramsey points out that they're living a lifestyle they can't afford, and that's what she must be worried about.&nbsp;
Trending: This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes, and you only need $100</a>.
"You have a lifestyle that's absolutely asinine, and that's nothing to do with a nine-year-old," Ramsey said. Alyssa tells the two finance experts that the money she needs for her daughter is for "just in case," an emergency savings fund. But Ramsey didn't buy it and explained, "But you're not doing anything about it. You got $3,000." He tells her in disbelief that her $3,000 in savings is just a "red herring" and "you're doing nothing about that except creating anxiety."&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Ramsey tells Alyssa that she and her husband have no idea where their money goes, so to help them, Ramsey puts them on a detailed written budget. <a href="https://www.benzinga.com/personal-finance/24/05/38922057/dave-ramsey-tells-caller-to-stop-funding-his-401-k-with-a-6-employer-match-while-in-debt-experts">Ramsey tells her that looking objectively at their finances</a>, he could easily see them being able to put aside at least $50,000 a year toward debt and should consider selling a car or two. He then dishes out some tough advice, "You live like no one else so that later you can give and live like no one else." To get out of debt, which he jokes has been so long it's like their family pet, Ramsey tells her it's going to be uncomfortable, but it has to be done.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Read Next:
<ul>
<li>Can you guess which type of investments Morgan Stanley says will reach $2.7 trillion by 2027?<a href="https://www.benzinga.com/money/percent"> It even offers up to 20% APY potential to accredited investors up to $300 back in bonus for new users.</a></li>
<li>This billion-dollar fund has invested in the next big real estate boom,<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> here's how you can join for $10.</a></li>
</ul>

Personal Finance

Dave Ramsey's Tough Advice For Woman Making $11,500/Month: 'Live Like No One Else So Later You Can Live And Give Like No One Else'

RBC Capital analyst Ashish Sabadra maintains TransUnion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRU#NYSE">TRU</a>) with a Outperform and raises the price target from $85 to $106.

RBC Capital Maintains Outperform on TransUnion, Raises Price Target to $106

WIIM

Colgate-Palmolive shares are trading higher after the company reported better-than-expected Q2 financial results.

RBC Capital analyst Walter Spracklin maintains Union Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) with a Outperform and lowers the price target from $281 to $275.

RBC Capital Maintains Outperform on Union Pacific, Lowers Price Target to $275

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>RBC Capital increased RTX Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) price target from $102 to $115. RBC Capital analyst Ken Herbert maintained a Sector Perform rating. RTX shares gained 1% to trade at $114.58 on Friday. <a href="https://www.benzinga.com/quote/RTX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs cut the price target for Coursera, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COUR#NYSE">COUR</a>) from $10.5 to $9. Goldman Sachs analyst Eric Sheridan maintained a Sell rating. Coursera shares gained 50% to trade at $11.12 on Friday. <a href="https://www.benzinga.com/quote/COUR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo boosted the price target for Tyler Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>) from $580 to $600. Wells Fargo analyst Michael Turrin maintained an Overweight rating. Tyler Technologies shares gained 3.1% to trade at $581.88 on Friday. <a href="https://www.benzinga.com/quote/TYL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler cut the price target for Dow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) from $68 to $64. Piper Sandler analyst Charles Neivert maintained an Overweight rating. Dow shares fell 0.1% to trade at $52.80 on Friday. <a href="https://www.benzinga.com/quote/DOW/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Macquarie boosted IMAX Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IMAX#NYSE">IMAX</a>) price target from $24 to $26. Macquarie analyst Chad Beynon maintained an Outperform rating. IMAX shares rose 1.8% to trade at $19.74 on Friday. <a href="https://www.benzinga.com/quote/IMAX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities raised the price target for Tractor Supply Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSCO#NASDAQ">TSCO</a>) from $289 to $293. Truist Securities analyst Scot Ciccarelli maintained a Buy rating. Tractor Supply shares rose 2.7% to trade at $264.49 on Friday. <a href="https://www.benzinga.com/quote/TSCO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Susquehanna cut Rambus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBS#NASDAQ">RMBS</a>) price target from $75 to $66. Susquehanna analyst Mehdi Hosseini maintained a Positive rating. Rambus shares gained 1.9% to trade at $57.87 on Friday. <a href="https://www.benzinga.com/quote/RMBS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Barclays boosted AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) price target from $187 to $200. Barclays analyst Carter Gould maintained an Overweight rating. AbbVie shares rose 2.1% to trade at $185.90 on Friday. <a href="https://www.benzinga.com/quote/ABBV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham raised LendingTree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TREE#NASDAQ">TREE</a>) price target from $56 to $67. Needham analyst Mayank Tandon maintained a Buy rating. LendingTree shares fell 2.3% to trade at $53.47 on Friday. <a href="https://www.benzinga.com/quote/TREE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank boosted Lockheed Martin Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) price target from $540 to $600. Deutsche Bank analyst Scott Deuschle upgraded the stock from Hold to Buy. Lockheed Martin shares rose 0.8% to trade at $525.61 on Friday. <a href="https://www.benzinga.com/quote/LMT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39984491/nvidia-lockheed-martin-and-2-other-stocks-insiders-are-selling">Nvidia, Lockheed Martin And 2 Other Stocks Insiders Are Selling</a></li>
</ul>

ABBV

COUR

IMAX

RMBS

TREE

TSCO

Lockheed Martin To Rally Over 14%? Here Are 10 Top Analyst Forecasts For Friday

The Biden-Harris Administration revealed that the U.S. Department of Commerce and Amkor Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) <a target="_blank" href="https://www.commerce.gov/news/press-releases/2024/07/biden-harris-administration-announces-preliminary-terms-amkor" rel="noreferrer noopener">signed </a>a preliminary memorandum of terms to provide up to $400 million in funding under the CHIPS and Science Act.
This funding supports Amkor&#8217;s planned $2 billion semiconductor packaging facility in Peoria, Arizona, which is expected to create 2,000 jobs and boost the domestic semiconductor supply chain.
Amkor announced in November 2023 its plans to build its first domestic outsourced semiconductor <a href="https://www.benzinga.com//node/39978603">assembly and test facility in Peoria, Arizona.</a>
Amkor&#8217;s Arizona facility will utilize technology, including 2.5D technology crucial for AI and high-performance computing.
President Biden&#8217;s CHIPS and Science Act, a pivotal part of his Investing in America agenda, aims to revitalize U.S. semiconductor manufacturing, enhance supply chain security, and foster job creation.
The proposed funding will help Amkor build the largest advanced packaging facility in the U.S., supporting high-performance computing, AI, communications, and automotive markets.
Amkor has secured approximately 55 acres and intends to build the campus with more than 500,000 square feet of clean room space. The first phase of the manufacturing facility is targeted to be ready for production within three years.
Commerce Secretary Gina Raimondo highlighted the significance of this investment in meeting the rising demand for AI chips and securing economic and national security.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/07/39966756/intel-taps-micron-leader-to-strengthen-ai-chip-strategy" rel="noreferrer noopener">Intel Taps Micron Leader To Strengthen AI Chip Strategy</a>
This initiative ensures that companies like Taiwan Semiconductor Manufacturing Company Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>), Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), and GlobalFoundries Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>) can package and test essential chips domestically, reinforcing the entire chip manufacturing process within the U.S. 
Amkor plans to take advantage of the Department of the Treasury&#8217;s Investment Tax Credit, which is expected to be up to&nbsp;25%&nbsp;of qualified capital expenditures.
In addition to the proposed direct funding of up to $400 million, the CHIPS Program Office would make approximately $200 million of proposed loans, which is part of the $75 billion in loan authority provided by the CHIPS and Science Act, available to Amkor under the preliminary memorandum of terms.
Price Action: AMKR shares are trading lower by 0.75% at $37.90 at last check Friday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39959836/amd-delays-desktop-cpu-zen-5-processor-launch-whats-going-on" target="_blank" rel="noreferrer noopener">AMD Delays Desktop CPU Zen 5 Processor Launch &#8211; What&#8217;s Going On?</a></li>
</ul>

Government

Regulations

Tech

General

AAPL

AMKR

What's Going On With Amkor Technology Stock Today?

Goldman Sachs analyst Joe Ritchie maintains GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) with a Buy and raises the price target from $196 to $220.

Goldman Sachs Maintains Buy on GE Vernova, Raises Price Target to $220

RBC Capital analyst Steven Shemesh maintains O'Reilly Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>) with a Outperform and lowers the price target from $1124 to $1115.

ORLY

RBC Capital Maintains Outperform on O'Reilly Automotive, Lowers Price Target to $1115

Goldman Sachs analyst Susan Maklari maintains Fortune Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBIN#NYSE">FBIN</a>) with a Buy and raises the price target from $75 to $86.

FBIN

Goldman Sachs Maintains Buy on Fortune Brands, Raises Price Target to $86

Goldman Sachs analyst Caitlin Burrows maintains First Industrial Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FR#NYSE">FR</a>) with a Sell and raises the price target from $46 to $52.

Goldman Sachs Maintains Sell on First Industrial Realty, Raises Price Target to $52

Wells Fargo analyst Derek Archila maintains argenx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) with a Overweight and raises the price target from $543 to $547.

ARGX

Wells Fargo Maintains Overweight on argenx, Raises Price Target to $547

On Friday, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a negative opinion on the approval of Eisai Co., Ltd (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ESALY#OTC">ESALY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ESALF#OTC">ESALF</a>) and Biogen Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38413442/biogeneisais-popular-alzheimers-drug-leqembi-is-seeing-slow-adoption-heres-why" rel="noreferrer noopener">lecanemab</a>.
The companies seek approval for the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody as a treatment for early AD (mild cognitive impairment due to Alzheimer&#8217;s disease (AD) <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/g39981134/update-on-regulatory-review-of-lecanemab-for-early-alzheimers-disease-in-the-european-union" rel="noreferrer noopener">and mild AD)</a>.
The committee <a target="_blank" href="https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024" rel="noreferrer noopener">considered</a> that the observed effect of Leqembi on delaying cognitive decline does not counterbalance the risk of serious side events associated with the medicine, in particular, the frequent occurrence of amyloid-related imaging abnormalities involving swelling and potential bleedings in the brain of patients who received Leqembi.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38410191/biogens-leqembi-commercial-ramp-up-modest-but-up-ticking-reports-mixed-bag-q1-earnings" rel="noreferrer noopener">Biogen&#8217;s Leqembi Commercial Ramp-Up Modest But Up Ticking, Reports Mixed Bag Q1 Earnings</a>.
In March, Biogen and Eisai faced a regulatory setback when Oral Explanation slated for March 19 at the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37897025/european-medicines-agency-delays-approval-decision-for-biogen-eisai-partnered-alzheimers-drug-lec" rel="noreferrer noopener">CHMP was postponed</a>.&nbsp;
In June, the FDA&#8217;s advisory committee delivered a favorable verdict on the Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Alzheimer&#8217;s treatment donanemab,&nbsp;declaring its benefits to surpass <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39277429/eli-lillys-donanemab-gains-favorable-fda-advisory-verdict-boosting-stock-potential-" rel="noreferrer noopener">the associated risks</a>.
&#8220;We are extremely disappointed by the CHMP&#8217;s negative opinion and understand that this may also be disappointing for the wider Alzheimer&#8217;s disease community,&#8221; said Lynn Kramer, Chief Clinical Officer at Eisai.
Eisai will seek re-examination of the CHMP opinion and work with the relevant authorities to ensure this treatment is available for eligible people living with early AD in the European Union (EU) as soon as possible.
Lecanemab has already been approved in the United States, Japan, China, South Korea, Hong Kong, and Israel, and it is being marketed in the U.S. (as&nbsp;Leqembi), Japan, and China.
AD currently affects 6.9 million people in Europe, which is expected to nearly double by 2050 as aging populations increase.
Eisai serves as the lead for lecanemab&#8217;s development and regulatory submissions globally. Both Eisai and Biogen co-commercialize and co-promote the product, and Eisai has final decision-making authority.
Price Action: BIIB stock is down 6.11% at $213.55 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/07/39935226/sage-biogen-shelve-development-of-nervous-system-disorder-drug-after-data-disappoints" target="_blank" rel="noreferrer noopener">Sage, Biogen Shelve Development Of Nervous System Disorder Drug After Data Disappoints</a>.</li>
</ul>
Photo via Shutterstock

Biotech

Health Care

BIIB

ESALF

ESALY

Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events

Minco Gold (TSE:MMM) has released an update. Minco Capital Corp. has announced the launch of a Normal Course Issuer Bid (NCIB) to repurchase up to ...

Minco Capital Initiates Share Buyback Program

Minco Gold (TSE:MMM) has released an update. Minco Capital Corp. successfully passed all resolutions at its Annual General Meeting, with unanimous ...

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Minco Cap

News

Latest news for Minco Cap (OTC:MGHCF) Stock

Tuesday, March 24, 2020

Monday, March 02, 2020